Shopping Cart
- Remove All
- Your shopping cart is currently empty
MAO A/HSP90-IN-1 (4-b) is a dual inhibitor of MAO A and HSP90, with IC50 values of 1.77 μM in glioblastoma (GBM) GL26 cells and 0.019 μM against HSP90α. This compound impairs MAO A activity, disrupts HSP90 binding, and downregulates HER2 and phospho-Akt expressions, thus inhibiting GBM growth. Additionally, it reduces PD-L1 expression, thwarting T cell activation and potential tumor immune evasion. MAO A/HSP90-IN-1 (4-b) is valuable for research into brain tumor-related diseases [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $1,520 | 8-10 weeks | |
50 mg | $1,980 | 8-10 weeks | |
100 mg | $2,500 | 8-10 weeks |
Description | MAO A/HSP90-IN-1 (4-b) is a dual inhibitor of MAO A and HSP90, with IC50 values of 1.77 μM in glioblastoma (GBM) GL26 cells and 0.019 μM against HSP90α. This compound impairs MAO A activity, disrupts HSP90 binding, and downregulates HER2 and phospho-Akt expressions, thus inhibiting GBM growth. Additionally, it reduces PD-L1 expression, thwarting T cell activation and potential tumor immune evasion. MAO A/HSP90-IN-1 (4-b) is valuable for research into brain tumor-related diseases [1]. |
Targets&IC50 | HSP90:0.019 μM, MAO-A:1.77 μM |
In vitro | MAO A/HSP90-IN-1 (4-b) inhibits GBM cell proliferation by suppressing MAO A and HSP90 at concentrations of 0.1-3 μM over 24 hours [1]. It showed an IC50 of 0.73 μM and 1.68 μM in different GL26 trials and 0.84 μM in U251R cells [1]. At 0, 0.35, 0.7, and 1.4 μM, it also reduced IFN-γ-induced PD-L1 expression in murine glioma GL26 cells after 24 hours [1]. |
In vivo | MAO A/HSP90-IN-1 (4-b) (25 mg/kg, intraperitoneal injection, daily) suppresses tumor growth in a murine GBM model [1]. |
Molecular Weight | 444.95 |
Formula | C24H29ClN2O4 |
Cas No. | 2927489-95-8 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.